- Home
- GMAB vs SAIA Comparison
GMAB vs SAIA Comparison
Compare GMAB & SAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- SAIA
- Stock Information
- Founded
- GMAB 1999
- SAIA 1924
- Country
- GMAB Denmark
- SAIA United States
- Employees
- GMAB N/A
- SAIA N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- SAIA Trucking Freight/Courier Services
- Sector
- GMAB Health Care
- SAIA Industrials
- Exchange
- GMAB Nasdaq
- SAIA Nasdaq
- Market Cap
- GMAB 12.1B
- SAIA 11.2B
- IPO Year
- GMAB N/A
- SAIA 2002
- Fundamental
- Price
- GMAB $24.14
- SAIA $375.92
- Analyst Decision
- GMAB Buy
- SAIA Buy
- Analyst Count
- GMAB 9
- SAIA 18
- Target Price
- GMAB $40.71
- SAIA $526.94
- AVG Volume (30 Days)
- GMAB 1.2M
- SAIA 465.4K
- Earning Date
- GMAB 05-01-2025
- SAIA 04-25-2025
- Dividend Yield
- GMAB N/A
- SAIA N/A
- EPS Growth
- GMAB 83.82
- SAIA 1.89
- EPS
- GMAB 16.85
- SAIA 13.51
- Revenue
- GMAB $2,988,286,182.00
- SAIA $3,209,074,000.00
- Revenue This Year
- GMAB $19.59
- SAIA $10.81
- Revenue Next Year
- GMAB $14.50
- SAIA $9.45
- P/E Ratio
- GMAB $14.08
- SAIA $27.83
- Revenue Growth
- GMAB 30.67
- SAIA 11.37
- 52 Week Low
- GMAB $18.64
- SAIA $358.90
- 52 Week High
- GMAB $31.88
- SAIA $624.55
- Technical
- Relative Strength Index (RSI)
- GMAB 71.05
- SAIA 30.67
- Support Level
- GMAB $23.63
- SAIA $371.73
- Resistance Level
- GMAB $24.11
- SAIA $420.09
- Average True Range (ATR)
- GMAB 0.37
- SAIA 25.79
- MACD
- GMAB 0.22
- SAIA -5.49
- Stochastic Oscillator
- GMAB 93.88
- SAIA 6.11
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About SAIA Saia Inc.
Saia ranks among the 10 largest less-than-truckload carriers in the United States, with more than 200 facilities and a fleet of more than 6,200 tractors and 20,800 trailers. As a national LTL carrier, the firm offers time-definite and expedited options for shipments ranging between 100 and 10,000 pounds. Saia ranks among the top-tier providers in terms of profitability.